ECSP003555A - Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion - Google Patents

Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion

Info

Publication number
ECSP003555A
ECSP003555A EC2000003555A ECSP003555A ECSP003555A EC SP003555 A ECSP003555 A EC SP003555A EC 2000003555 A EC2000003555 A EC 2000003555A EC SP003555 A ECSP003555 A EC SP003555A EC SP003555 A ECSP003555 A EC SP003555A
Authority
EC
Ecuador
Prior art keywords
salt
mammals
diphosphate
diffosphate
homoerithromycin
Prior art date
Application number
EC2000003555A
Other languages
English (en)
Inventor
Robert John Rafka
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP003555A publication Critical patent/ECSP003555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Esta invención se refiere a una nueva sal dfosfato cristalina de (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[ [2,6-didesoxi-3-C-metil-4-C-[(propilamino)metil]&-Lribo'hexopiranosil]oxi]-2-etil-3,4,10-trihidroxi-3,5,8,10,12,14-hexametil-11- [ [3,4,6-tridesoxi-3-(dimetilamino) - B-D-xilo-hexopiranosil]oxi]-1-oxa-6-azaciclopentadecan-15-ona que es útil como agente antibacteriano y antiprotozoario en mamíferos.Esta invención también se refiere a composiciones farmaceúticas que contienen la base libre de la sal difosfato y a los procedimientos de tratamiento de infecciones bacterianas y protozoarias en mamíferos, mediante la administración de la base libre de la sal difosfato a mamíferos que requieren dicho tratamiento. La base libre de sal difosfato de la presente invención posee una potente actividad contra diversas infecciones bacterianas y protozoarias cuando se administra por vía parenteral a mamíferos.
EC2000003555A 1999-06-30 2000-06-30 Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion ECSP003555A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14168199P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
ECSP003555A true ECSP003555A (es) 2002-01-25

Family

ID=22496734

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003555A ECSP003555A (es) 1999-06-30 2000-06-30 Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion

Country Status (42)

Country Link
US (3) US6465437B1 (es)
EP (1) EP1189913B1 (es)
JP (1) JP2003503506A (es)
KR (1) KR100442508B1 (es)
CN (2) CN1358188A (es)
AP (1) AP2001002370A0 (es)
AR (1) AR035551A1 (es)
AT (1) ATE286906T1 (es)
AU (1) AU772277B2 (es)
BG (1) BG65587B1 (es)
BR (1) BR0012091A (es)
CA (1) CA2376748C (es)
CO (1) CO5190679A1 (es)
CZ (1) CZ20014571A3 (es)
DE (1) DE60017399T2 (es)
EA (1) EA004235B1 (es)
EC (1) ECSP003555A (es)
EE (1) EE05068B1 (es)
ES (1) ES2233380T3 (es)
GT (2) GT200000105A (es)
HN (1) HN2000000090A (es)
HR (1) HRP20010919B1 (es)
HU (1) HUP0201693A3 (es)
IL (1) IL146408A0 (es)
IS (1) IS6159A (es)
MA (1) MA26745A1 (es)
MX (1) MXPA02000058A (es)
MY (1) MY133360A (es)
NO (1) NO20016221D0 (es)
OA (1) OA11965A (es)
PA (1) PA8496901A1 (es)
PE (1) PE20010287A1 (es)
PL (1) PL201891B1 (es)
PT (1) PT1189913E (es)
SK (1) SK286243B6 (es)
TN (1) TNSN00143A1 (es)
TR (1) TR200103834T2 (es)
UA (1) UA71013C2 (es)
UY (1) UY26221A1 (es)
WO (1) WO2001002414A1 (es)
YU (1) YU88701A (es)
ZA (1) ZA200110453B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6791660B1 (en) * 2002-02-12 2004-09-14 Seiko Epson Corporation Method for manufacturing electrooptical device and apparatus for manufacturing the same, electrooptical device and electronic appliances
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
WO2013013834A1 (en) 2011-07-27 2013-01-31 Farma Grs, D.O.O. New crystalline forms of tulathromycin
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN110885351A (zh) * 2019-12-17 2020-03-17 海门慧聚药业有限公司 泰拉霉素磷酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JP2003512290A (ja) * 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての８ａ−アザライド
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків
HUP0201341A3 (en) * 1999-05-18 2003-03-28 Pfizer Prod Inc Novel crystalline forms of a macrolide antibiotic, process for its preparation and pharmaceutical compositions containing it
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition

Also Published As

Publication number Publication date
CA2376748A1 (en) 2001-01-11
EP1189913A1 (en) 2002-03-27
GT200000105AA (es) 2001-12-20
EA200101178A1 (ru) 2002-06-27
HN2000000090A (es) 2001-04-20
JP2003503506A (ja) 2003-01-28
AR035551A1 (es) 2004-06-16
US20030092642A1 (en) 2003-05-15
WO2001002414A1 (en) 2001-01-11
EE200100699A (et) 2003-02-17
IL146408A0 (en) 2002-07-25
ES2233380T3 (es) 2005-06-16
ZA200110453B (en) 2003-03-04
MY133360A (en) 2007-11-30
PL352900A1 (en) 2003-09-22
NO20016221L (no) 2001-12-19
CN101220067A (zh) 2008-07-16
PA8496901A1 (es) 2002-08-26
DE60017399T2 (de) 2006-03-30
TR200103834T2 (tr) 2002-05-21
BR0012091A (pt) 2002-04-02
EP1189913B1 (en) 2005-01-12
YU88701A (sh) 2004-09-03
HRP20010919B1 (en) 2005-06-30
MA26745A1 (fr) 2004-12-20
TNSN00143A1 (fr) 2005-11-10
OA11965A (en) 2006-04-12
GT200000105A (es) 2001-12-20
SK18922001A3 (sk) 2002-04-04
SK286243B6 (sk) 2008-06-06
EE05068B1 (et) 2008-08-15
AP2001002370A0 (en) 2001-12-31
ATE286906T1 (de) 2005-01-15
PL201891B1 (pl) 2009-05-29
AU772277B2 (en) 2004-04-22
AU4943900A (en) 2001-01-22
PE20010287A1 (es) 2001-03-05
UA71013C2 (uk) 2004-11-15
KR20020016875A (ko) 2002-03-06
CO5190679A1 (es) 2002-08-29
MXPA02000058A (es) 2002-07-02
DE60017399D1 (de) 2005-02-17
HRP20010919A2 (en) 2003-02-28
PT1189913E (pt) 2005-04-29
US20040209826A1 (en) 2004-10-21
CN1358188A (zh) 2002-07-10
BG106123A (en) 2002-05-31
US7297682B2 (en) 2007-11-20
HUP0201693A3 (en) 2003-03-28
IS6159A (is) 2001-11-13
BG65587B1 (bg) 2009-01-30
EA004235B1 (ru) 2004-02-26
UY26221A1 (es) 2001-01-31
NO20016221D0 (no) 2001-12-19
CA2376748C (en) 2006-03-14
US6861412B2 (en) 2005-03-01
HUP0201693A2 (en) 2002-10-28
KR100442508B1 (ko) 2004-07-30
CZ20014571A3 (cs) 2002-04-17
US6465437B1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
BR9814601A (pt) "macrólidos"
BR0112863A (pt) Antibióticos macrólidos
BR9714287A (pt) Antibiótico cristalino designado solvato 6-o-metileritromicina forma 0, solvato de 6-o-metileritromicina forma 0, composição, processos para tratamento de infecções bacterianas em um mamìfero hospedeiro com necessidade de tal tratamento e para preparação de solvato de 6-o-metileritomicina a forma 0, 6-o-metileritromicina forma 0--etanolato, suspensão para administração oral, e, complexo de solvato de 6-o-metileritromicina a forma 0-carbÈmero.
BG101485A (en) Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides
BR0209918A (pt) Formas cristalinas da azitromicina
PT952835E (pt) Metodo de tratamento de doenca cardiaca causada por chlamidia pneumoniae
BR9916969A (pt) Antibióticos cetólidos
AP9801253A0 (en) 9-Oxime erythromycin derivatives.
CA2132429A1 (en) Alkylthio alkyl avermectins are active antiparasitic agents
BR9306741A (pt) Derivados de macrólidos antibióticos com anel de 16 membros
ECSP003555A (es) Sal difosfato de un derivado de 4 sustituido- 9- desoxo-9a-aza-9a-homoeritromicina y su composicion
AP2002002652A0 (en) The use of azalide antibiotic composition for treating or preventing a bacterial or protozoal infection in mammals.
BG104340A (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
PT1133511E (pt) Novos intermediarios e processo para preparar um agente antibiotico macrolido a partir deles
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
MD970243A (en) 9-O-Oximes erythromycin A derivatives, possessing antibiotic properties
IL126625A0 (en) 6-o-substituted erythromycin compounds and method for making same
TNSN04166A1 (en) Isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2332686A1 (en) Novel 13 and 14-membered antibacterial and prokinetic macrolides and their intermediates